Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor

Radiation Medicine - Medical Imaging and Radiation Oncology

Volumn 22, Issue 4, 2004, Pages 205-211

  Monzen, Hajime ^a   Griffin, Robert J ^b   Williams, Brent W ^b   Amano, Morikazu ^b   Ando, Satoshi ^c   Hasegawa, Takeo ^c  

^a OTSU RED CROSS HOSPITAL   (Japan)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Antivascular effect; Arsenic trioxide; Magnetic resonance imaging (MRI); Radioresponse; Solid tumor

Indexed keywords

ARSENIC TRIOXIDE; EOSIN; GADOLINIUM PENTETATE; HEMATOXYLIN; PENTOBARBITAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG MECHANISM; HISTOPATHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROMYELOCYTIC LEUKEMIA; RADIOSENSITIVITY; RADIOSENSITIZATION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR NECROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; BLOOD VESSELS; CARCINOMA, SQUAMOUS CELL; COLORING AGENTS; GROWTH INHIBITORS; HINDLIMB; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C3H; MICE, INBRED STRAINS; NECROSIS; OXIDES; RADIATION-SENSITIZING AGENTS; REGIONAL BLOOD FLOW; SKIN NEOPLASMS; TUMOR STEM CELL ASSAY;

EID: 4644238227     PISSN: 02882043     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist, 6: 3-10, 2001.
2. Jolliffe DM. A history of the use of arsenicals in man. J R Soc Med, 86: 287-289, 1993.
3. Sears DA. History of the treatment of chronic myelocytic leukemia. Am J Med Sci, 296: 85-86, 1998.
4. Gallagher RE. Arsenic-new life for an old potion. N Engl J Med, 339: 1389-1391, 1998.
5. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med, 339: 1341-1348, 1998.
6. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89: 3354-3360, 1997.
7. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood, 88: 1052-1061, 1996.
8. Zhu J, Koken MH, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA, 94: 3978-3983, 1997.
9. Shao W, Fanelli M, Ferrara FF, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst, 90: 124-133, 1998.
10. Zhu XH, Shen YL, Jing YK, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst, 91: 772-778, 1999.
11. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res, 62: 3893-3903, 2002.
12. Hughes MF. Aresnic toxicity and potential mechanisms of action. Toxicol Lett, 133: 1-16, 2002.
13. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res, 59: 6033-6037, 1999.
14. Griffin RJ, Lee SH, Rood KL, et al. Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia, 2: 555-560, 2000.
15. Lew YS, Kolozsvary A, Brown SL, Kim JH. Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor. Cancer Res, 62: 4202-4205, 2002.
16. Chun YJ, Park IC, Park MJ, et al. Enhancement of radiation response in human cervical cancer in vitro and in vivo by arsenic trioxide (As2O3). FEBS Lett, 519: 195-200, 2002.
17. Griffin RJ, Monzen H, Williams BW, Park H, Lee SH, Song CW. Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hyperthermia, 19: 575-589, 2003.
18. Niendorf HP, Laniado M, Semmler W, Schorner W, Felix R. Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors. AJNR Am J Neuroradiol, 8: 803-815, 1987.
19. Jones EL, Douple EB. The effect of in vivo GSH depletion on thermosensitivity, radiosensitivity and thermal radiosensitization. Int J Hyperthermia, 6: 951-955, 1990.
20. Fu KK. Biological basis for the interaction of chemotherapeutic agents and radiation therapy. Cancer, 55: 2123-2130, 1985.
21. Xie D, Yin S, Ou Y, et al. Arsenic trioxide (As(2)O(3)) induced apoptosis and its mechanisms in a human esophageal squamous carcinoma cell line. Chin Med J, 115: 280-285, 2002.
22. Devine SM, Vokes EE, Weichselbaum RR. Chemotherapeutic and biologic radiation enhancement. Curr Opin Oncol, 3: 1087-1095, 1991.